Study: common form of breast cancer may warrant less aggressive treatment
‘We’re not suggesting a do-nothing, wait-and-see approach,’ says lead researcher in study of more than 100,000 women with breast cancer of the milk ductWomen who are treated for what has come to be considered a non-invasive breast cancer of the milk duct could need less treatment – not more – a new study of more than 100,000 women indicates. The study, which appears in the Journal of the American Medical Association (JAMA) Oncology this week, found that women treated for ductal carcinoma in situ, a group of abnormal cells found in the milk duct, were not significantly less likely to die of breast cancer than wome...
Source: Guardian Unlimited Science - August 20, 2015 Category: Science Authors: Jessica Glenza Tags: Breast cancer US news Health Medical research Science Source Type: news
Breast Cancer Treatment and D.C.I.S.: Answers to Questions About New Findings
A large study following 100,000 patients with ductal carcinoma in situ for 20 years raises doubts about the standard treatment for the conditions. (Source: NYT Health)
Source: NYT Health - August 20, 2015 Category: Consumer Health News Authors: GINA KOLATA Tags: Mastectomy DCIS Breast Cancer Medicine and Health Source Type: news
Study: DCIS is more deadly than thought
Women diagnosed with ductal carcinoma in situ (DCIS) are at twice the risk...Read more on AuntMinnie.comRelated Reading:Should women over 75 be screened for breast cancer?, April 29, 2015Mammo false positives, overdiagnosis cost U.S. $4B per year, April 7, 2015JAMA: Doctors often disagree on breast biopsy results, March 18, 2015Risk-based screening misses more than 75% of breast cancers, December 2, 2014Digital mammography finds DCIS most likely to become cancer, April 16, 2014 (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 20, 2015 Category: Radiology Source Type: news
Study examines breast cancer mortality after ductal carcinoma in situ diagnosis
Researchers estimate the 20-year breast cancer-specific death rate for women diagnosed with ductal carcinoma in situ to be 3.3 percent, although the death rate is higher for women diagnosed before age 35 and for black women, according to an article (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 20, 2015 Category: Science Source Type: news
Large DCIS Study Is 'Compelling Case' for ChangeLarge DCIS Study Is 'Compelling Case' for Change
Currently, most cases of ductal carcinoma in situ (DCIS) are treated with the standard of lumpectomy plus radiotherapy. But is it all necessary with such a very low death rate at 20 years? Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 20, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Doubt Is Raised Over Value of Surgery for Breast Lesion at Earliest Stage
Almost all women given a diagnosis of ductal carcinoma in situ, considered a possible precursor to breast cancer, have a lumpectomy or mastectomy, but data show they may not benefit. (Source: NYT Health)
Source: NYT Health - August 20, 2015 Category: Consumer Health News Authors: GINA KOLATA Tags: Mastectomy Research Steven A. Narod Breast Cancer D.C.I.S. Source Type: news
Study examines breast cancer mortality after ductal carcinoma in situ diagnosis
(The JAMA Network Journals) Researchers estimate the 20-year breast cancer-specific death rate for women diagnosed with ductal carcinoma in situ to be 3.3 percent, although the death rate is higher for women diagnosed before age 35 and for black women, according to an article published online by JAMA Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 20, 2015 Category: Cancer & Oncology Source Type: news
Ductal carcinoma in situ carries a higher risk of death than previously thought
(Women's College Hospital) Women diagnosed with ductal carcinoma in situ (DCIS) are twice as likely to die from breast cancer compared to the general US population, according to a new study led by Dr. Steven Narod. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 20, 2015 Category: Cancer & Oncology Source Type: news
Results Support Active Surveillance for Low-Grade DCISResults Support Active Surveillance for Low-Grade DCIS
A first-of-its-kind study of American patients with ductal carcinoma in situ (DCIS) shows that surgery did not improve survival in low-grade disease. So why not skip surgery? Medscape Medical News (Source: Medscape ObGyn and Womens Health Headlines)
Source: Medscape ObGyn and Womens Health Headlines - June 11, 2015 Category: OBGYN Tags: Hematology-Oncology News Source Type: news
Benefit of surgery for ductal carcinoma in-situ investigated
(Brigham and Women's Hospital) In a study published in JAMA Surgery on June 3, researchers from Brigham and Women's Hospital report that breast surgery performed at or shortly after a diagnosis of low-grade ductal carcinoma in-situ (DCIS) did not significantly change patients' survival rate. The team finds that the survival rate for those with intermediate- and high-grade DCIS does improve with surgery, but the work raises concerns about overtreatment and the necessity and benefit of surgery for all patients with low-grade DCIS. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 3, 2015 Category: Cancer & Oncology Source Type: news
Benefit of Surgery for Ductal Carcinoma In-Situ (DCIS) Investigated
Study finds that breast surgery offers less survival benefit for low-grade DCIS patients. (Source: BWH News)
Source: BWH News - June 3, 2015 Category: Hospital Management Source Type: news
Benefit of Surgery for Ductal Carcinoma In-Situ (DCIS) Investigated
Study finds that breast surgery offers less survival benefit for low-grade DCIS patients. (Source: BWH for Journalists)
Source: BWH for Journalists - June 3, 2015 Category: Research Source Type: news
Anastrozole prevents recurrence more than tamoxifen in some with noninvasive breast cancer
Anastrozole provides a significant benefit compared with tamoxifen in preventing recurrence after a lumpectomy and radiation therapy in postmenopausal women ages 60 years or younger who had DCIS (ductal carcinoma in situ), a common diagnosis of non-invasive breast cancer. In women over age 60, it works as well as tamoxifen. The benefit reported in this trial appeared later in follow up of the women in the study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 1, 2015 Category: Science Source Type: news
Anastrozole prevents recurrence more than tamoxifen in some with noninvasive breast cancer
(Loyola University Health System) Anastrozole provides a significant benefit compared with tamoxifen in preventing recurrence after a lumpectomy and radiation therapy in postmenopausal women ages 60 years or younger who had DCIS (ductal carcinoma in situ), a common diagnosis of non-invasive breast cancer. In women over age 60, it works as well as tamoxifen. These findings were presented today at the 2015 ASCO Annual Meeting in Chicago. The benefit reported in this trial appeared later in follow up of the women in the study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 30, 2015 Category: Cancer & Oncology Source Type: news
